The Catalyst

Most Recent Posts

06.16.11 | By Kate Connors
In recent months, there has been a good deal of discussion about R&D productivity, with references, for example, to a slight decline in the average number of new medicines approved by the FDA in recent years. This, of course, is at a time when we continue to see record investment in R&D, with America's biopharmaceutical research companies last year investing $67.4 billion in the discovery and development of new medicines.
06.15.11 | By Kate Connors

06.14.11 | By Kate Connors

An op-ed in the Cleveland Plain Dealer by William Burga, a former president of the Ohio AFL-CIO, is a good reminder that support for patent reform - which I've written about in the past - is important not just to biopharmaceutical research companies, but to all sectors that are stimulated by the patent system.

06.13.11 | By Kate Connors

Summer is finally upon us, and though at times it almost seems too steamy to venture outside, it serves as a good reminder about the importance of taking care of your skin.

06.10.11 | By Christian Clymer

06.10.11 | By Kate Connors

Yesterday, PhRMA President and CEO John J. Castellani spoke at the Personalized Medicine Coalition's 7th annual State of Personalized Medicine Luncheon. He spoke about the many challenges confronting the biopharmaceutical sector as it increasingly turns its attention to personalized medicine, but also about the promise that the field offers.

06.09.11 | By Kate Connors

The Association of Nurses in AIDS Care was founded in 1987 with a mission of promoting the individual and collective professional development of nurses involved in the delivery of healthcare to patients with HIV/AIDS. ANAC is a member-driven, chapter-based organization of over 2,500 nurses united to advocate for their HIV patients and advance HIV/AIDS research and standards of HIV care. In its goals is the abiding commitment to the prevention of further HIV infection.

06.09.11 | By Kate Connors

Ezra Klein's column in yesterday's Washington Post on the Medicare prescription drug benefit discusses why costs in Part D have come in beneath expectations. He makes some fair points. But Ezra overlooks the program's unique design that is helping to keep costs far below initial projections and coverage affordable for beneficiaries.

06.08.11 | By Kate Connors

We're focused this week on the past 30 years of HIV/AIDS and how the disease - and with it, the world - has changed in those three decades.

But what does 30 years really mean?

To me, it's nearly a lifetime. To early patients who have survived and are with us today, it may feel like a miracle.

To help put it into context, some of my colleagues made an incredibly moving brief video about the timeline of AIDS research and advances.

06.07.11 | By Kate Connors

AstraZeneca CEO David Brennan, in his role as President of the International Federation of Pharmaceutical Manufacturers and Associations, gave the

06.06.11 | By Kate Connors

Unsurprisingly, coverage of the AIDS 30th anniversary has been heating up. On Friday on NPR's All Things Considered, University of Alabama-Birmingham's Dr. Michael Saag spoke about spending his entire career treating AIDS, as he began his residency in 1981.

06.06.11 | By Kate Connors

Grady, my partner in blogging, is enviably vacationing in the south of France, so you'll be hearing even more from me in the next 10 days or so. I don't know who is luckiest: Grady, me or you...

Anyway, two topics will be front and center throughout the week: the progress we've made since HIV/AIDS was first formally recognized 30 years ago and the tremendous promise of personalized medicine. As you'll see, there are many common threads in these separate but very much entwined story lines.

06.06.11 | By John Castellani

Yesterday, June 5, was the 30th anniversary of the first time a medical journal mentioned patients suffering from the disease that we now know as HIV/AIDS.

06.03.11 | By Kate Connors

CNN today ran a segment on the problem of counterfeit medicines.

It serves as a reminder that American patients currently enjoy peace of mind knowing that their prescription medicines are safe and effective, as determined by the US Food and Drug Administration (FDA), and not counterfeit.

06.02.11 | By Preet Bilinski

Biopharmaceutical companies led to a nearly 18 percent increase in corporate philanthropy in 2010, according to an article published this morning by Reuters.

Pages